Miscellaneous Healthcare

BULLFROG AI HOLDINGS INC C/WTS EXP (TO PUR COM)

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

BFRGW

BFRG

ARKG

LABU

BullFrog AI Holdings, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 11, 2026, with a new deadline of April 29, 2026, for receiving shareholder proposals and director nominations. This change clarifies the timeline for investor participation in the proxy process, as previous deadlines are no longer valid. The company is governed by U.S. securities laws and engages with shareholders through annual meetings and formal proxy processes.

Tip Ranks

Bullfrog AI

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

BullFrog AI Sets 2026 Annual Meeting, Proposal Deadline

SBIO

Bullfrog AI Holdings shares are trading higher after the company announced that it secured funding into late 2027.

benzinga_article

ALPS Medical Breakthrough

VG Health

Health Care Select Sector SPDR

A recent commercial deal with a leading global pharmaceutical company ranked in the top 5 has set the foundation for further enterprise negotiations. This agreement marks the beginning of a burgeoning pipeline of discussions with other potential partners. The company has secured a runway extending into late 2027, indicating a stable and promising outlook for future collaborations.

Unusual Whales

iShares US Pharma

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

BullFrog AI Holdings has regained compliance with Nasdaq's $2.5M stockholders' equity requirement after raising at least $3.45 million through common stock sales. The company received a notice of noncompliance but has now addressed the deficiency, reducing delisting risk. However, there are uncertainties regarding the outcome of the Nasdaq hearing and ongoing compliance.

TradingView

BullFrog AI Holdings regains Nasdaq equity compliance after $3.45M in equity raises

VRAX

In Tuesday's intraday session, Apellis Pharmaceuticals saw a significant gain of 135.5%, reaching $40.26, with a market cap of $2.1 billion. Other notable gainers included Bullfrog AI Hldgs (+62.85%), Centessa Pharmaceuticals (+44.76%), and Virax Biolabs Group (+29.84%). Conversely, IO Biotech experienced a sharp decline of 73.2%, dropping to $0.05, followed by PepGen (-63.72%) and Iterum Therapeutics (-45.74%). The Q4 earnings reports influenced these movements, with several companies reporting significant changes in stock prices.

Virax Biolabs

PepGen

Iterum Therap

Centessa Pharmaceuticals

IO Biotech

Invesco Nasdaq Biotechnology ETF

Apellis Pharma

iShares Global Healthcare

ITERUM THERAPEUTICS PLC

IO BIOTECH INC

12 Health Care Stocks Moving In Tuesday's Intraday Session

Bullfrog AI (BFRG.US) has sparked short-term rebound potential, with market bullish sentiment concentrated and released. The current stock price remains above the 5-day and 10-day moving averages, providing some upward support. Market sentiment has driven capital inflow, with significant strengthening of fund movement during the day. Accompanied by recovering inventory data, investor confidence has been greatly boosted, triggering a short-term chasing rally. Such rebounds typically attract speculative funds, positively influencing the short-term price trend. However, the key to whether the rebound can be sustained lies in the accompanying trading volume; investors need to remain vigilant to prevent reversal risks due to insufficient trading volume. In this context, investors should also pay attention to the potential impact of sudden adverse news on stock prices. If changes in news lead to fluctuations in market sentiment, a decline in trading volume may make it difficult for the rebound to continue. Investors should respond flexibly and closely observe changes in trading

Technical Forecast

Morning Trend | Bullfrog AI sees capital inflow, short-term opportunities emerge?

Major U.S. indexes closed mixed on Monday. Micron Technology's stock fell 9.88% to $321.80 after a significant rally, attributed to profit-taking. Fannie Mae surged 51.23% to $7.35, driven by expectations of exiting conservatorship. Bullfrog AI skyrocketed 106.57% to $1.05 following a key agreement for drug target identification. ServiceNow rose 5.59% to $104.97, despite trading below key moving averages. AMC gained 3.35% to $0.98, boosted by strong box office performance. Micron shows strong momentum but is under pressure.

- Major U.S. indexes showed mixed results on Monday, with the Dow rising by 0.1%, while the S&P 500 and Nasdaq decreased by 0.39% and 0.7%, respectively.  
- Micron Technology's stock fell nearly 10% after a significant previous rally, influenced by profit-taking post-strong earnings, while Fannie Mae surged over 51% due to speculation about exiting conservatorship.  
- Notable gains also included Bullfrog AI up 106% on a drug discovery agreement and ServiceNow increasing 5.59% following a new partnership with Ericsson, despite trading pressures.

Fidelity

AMC ENT

ServiceNow

SPDR S&P Software

Invesco Leisure & ENT ETF

GraniteShares 2x Long MU Daily ETF

iShares Semiconductor ETF

VanEck Semiconductor ETF

SPDR S&P Semicon

Federal National Mortgage Association

Micron Tech

Direxion Semicon Bull 3X

Invesco Semiconductors ETF

Micron Technology, Fannie Mae, Bullfrog AI, ServiceNow And AMC: Why These 5 Stocks Are On Investors' Radars Today

BullFrog AI Signs Major AI Drug Discovery Partnership

BullFrog AI Signs Major AI Drug Discovery Partnership

BullFrog AI has signed a one-year Feasibility Agreement with an undisclosed global pharmaceutical company to utilize its bfLEAP platform for identifying drug targets for major depressive disorder (MDD). The agreement includes milestone payments for deliverables such as prioritized targets and causal gene networks. The client may secure exclusive rights to a final target for three years and can terminate the agreement with 30 days' notice. The agreement was effective from March 27, 2026, as per the SEC filing.

BullFrog AI Enters One-Year Feasibility Pact With Global Pharma to Advance MDD Targets

BULLFROG AI HOLDINGS INC C/WTS EXP (TO PUR COM)(BFRGW.US)

BullFrog AI Sets 2026 Annual Meeting, Proposal Deadline

Bullfrog AI Holdings shares are trading higher after the company announced that it secured funding into late 2027.

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

BullFrog AI Holdings regains Nasdaq equity compliance after $3.45M in equity raises

12 Health Care Stocks Moving In Tuesday's Intraday Session